

Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment. A descriptive analysis: VALUE study

**Carlos A. Jiménez-Ruiz¹, Marcos García², Manuel A. Martínez³,
Jacobó Sellarés⁴, María Ángeles Jiménez-Fuentes⁵, Lourdes Lázaro⁶,
Esther Rodríguez⁵, Concepción Rodríguez³, Oriol Armengol⁷, Emilia Abad⁴,
Teresa Peña⁶, Adolfo Domenech², Juan Antonio Riesco⁸**

¹Smoking Cessation Service, Madrid

²Smoking Unit, Pulmonology Department, Hospital Carlos Haya, Málaga

³Unidad de Gestión clínica de Neumología/Unidad de Tabaquismo, Hospital San Agustín, Avilés

⁴Pulmonology Department, Hospital Clinic, Barcelona

⁵Hospital Universitario Valle de Hebron, Barcelona

⁶Pulmonology Department, Hospital Universitario, Burgos

⁷ABS Poblenou, Barcelona

⁸Smoking Unit. Pulmonology Department, Hospital S. Pedro de Alcántara, Cáceres, Spain

Supplementary Table 1. Reasons for discontinuation of the study.

Change in work centre of the investigator / reasons related to investigator	14
Lack of clear intention to abstain	4
Discontinuation of the study due to change of work, address or mobility problem	3
Discontinuation of the study due to treatment-attributed adverse events	2
Discontinuation of smoking and the study before completing all the visits	3
Death	2
Data recorded after deadline	1
Appearance of malignant neoplasm of the lung	1
Discontinuation for reasons of anxiety related to situational factors	1
Acute worsening of COPD after the baseline visit, prior to starting treatment	1
Not starting the study after the baseline visit / unknown	8